At least five law firms are providing legal advice on an agreement by a private equity consortium, including Elliot Investment Management, to buy drug research services company Syneos Health Inc. for about $4.4 billion.
Latham & Watkins is advising Syneos Health on the agreement, which calls for the consortium to pay $43 per share in cash for the North Carolina-based company. That represents a 24% premium to Syneos Health’s closing stock price on Feb. 13, before news of the potential sale emerged, according to a statement.
Gibson Dunn is counseling Elliot on the deal, which is valued at about $7.1 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.